Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

Transcriptional Profiling of Age-Associated Gene Expression Changes in Human Circulatory CD1c+ Myeloid Dendritic Cell Subset.

Rahmatpanah F, Agrawal S, Scarfone VM, Kapadia S, Mercola D, Agrawal A.

J Gerontol A Biol Sci Med Sci. 2018 Apr 28. doi: 10.1093/gerona/gly106. [Epub ahead of print]

PMID:
29718193
2.

Assessing Researcher Needs for a Virtual Biobank.

van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S.

Biopreserv Biobank. 2017 Jun;15(3):203-210. doi: 10.1089/bio.2016.0009. Epub 2016 Dec 8.

3.

When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Yokoyama NN, Denmon A, Uchio EM, Jordan M, Mercola D, Zi X.

Curr Pharmacol Rep. 2015 Dec 1;1(6):420-433. Epub 2015 Apr 14.

4.

Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.

Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X.

Oncotarget. 2015 Dec 8;6(39):41809-24. doi: 10.18632/oncotarget.6166.

5.

Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.

Zhu J, Pan C, Jiang J, Deng M, Gao H, Men B, McClelland M, Mercola D, Zhong WD, Jia Z.

Oncotarget. 2015 Jun 30;6(18):16757-65.

6.

Correction: Overexpression of periostin in stroma positively associated with aggressive prostate cancer.

Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri R, Chia D, Zhang Z, Mercola D, Zhang H.

PLoS One. 2015 Jun 4;10(6):e0130333. doi: 10.1371/journal.pone.0130333. eCollection 2015. No abstract available.

7.

Overexpression of periostin in stroma positively associated with aggressive prostate cancer.

Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri R, Chia D, Zhang Z, Mercola D, Zhang H.

PLoS One. 2015 Mar 17;10(3):e0121502. doi: 10.1371/journal.pone.0121502. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0130333.

8.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

9.

The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma.

Chen X, McClelland M, Jia Z, Rahmatpanah FB, Sawyers A, Trent J, Duggan D, Mercola D.

Oncotarget. 2015 Jan 30;6(3):1865-73.

10.

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.

Baron VT, Pio R, Jia Z, Mercola D.

Br J Cancer. 2015 Feb 17;112(4):755-64. doi: 10.1038/bjc.2014.622. Epub 2015 Jan 29.

11.

A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Rahmatpanah FB, Jia Z, Chen X, Char JE, Men B, Franke AC, Jones FE, McClelland M, Mercola D.

Oncotarget. 2015 Jan 20;6(2):1286-301.

12.

Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Yokoyama NN, Shao S, Hoang BH, Mercola D, Zi X.

Am J Clin Exp Urol. 2014 Apr 15;2(1):27-44.

13.

Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-β and IGF signaling.

Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi X, McClelland M, Mercola D.

Biomed Res Int. 2014;2014:502093. doi: 10.1155/2014/502093. Epub 2014 Jun 25. Review.

14.

The transcription factor EGR1 localizes to the nucleolus and is linked to suppression of ribosomal precursor synthesis.

Ponti D, Bellenchi GC, Puca R, Bastianelli D, Maroder M, Ragona G, Roussel P, Thiry M, Mercola D, Calogero A.

PLoS One. 2014 May 1;9(5):e96037. doi: 10.1371/journal.pone.0096037. eCollection 2014.

15.

Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.

Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D.

PLoS One. 2014 Jan 21;9(1):e85010. doi: 10.1371/journal.pone.0085010. eCollection 2014.

16.

A gradient boosting algorithm for survival analysis via direct optimization of concordance index.

Chen Y, Jia Z, Mercola D, Xie X.

Comput Math Methods Med. 2013;2013:873595. doi: 10.1155/2013/873595. Epub 2013 Nov 20.

17.

Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.

Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, Mercola D, McGuire KL.

Int J Cancer. 2014 Jan 1;134(1):81-91. doi: 10.1002/ijc.28326. Epub 2013 Jul 13.

18.

Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X.

Curr Cancer Drug Targets. 2013 Jun;13(5):558-79. Review.

19.

Natural products and transforming growth factor-beta (TGF-β) signaling in cancer development and progression.

Lee C, Zhang Q, Kozlowski J, Brendler C, B Soares M, Dash A, McClelland M, Mercola D.

Curr Cancer Drug Targets. 2013 Jun;13(5):500-5. Review.

20.

Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.

Pio R, Jia Z, Baron VT, Mercola D; UCI NCI SPECS Consortium of the Strategic Partners for the Evaluation of Cancer Signatures-Prostate Cancer.

PLoS One. 2013;8(1):e54096. doi: 10.1371/journal.pone.0054096. Epub 2013 Jan 14.

Supplemental Content

Loading ...
Support Center